Vendor, TEL-AVIV, ISR
Redhill Biopharma Ltd.
UEI NKN1XZ8D6KG5, CAGE 2967A
1 award and $733,382 obligated between September 27, 2024 and September 3, 2025, 100% under full and open competition, against 1.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $733,382 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $733,382 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50124C00059Definitive Contract, September 27, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Redhill Biopharma Ltd-Opaganib as Host-Directed Therapeutic for Ebola Virus DiseaseNAICS 541714, PSC AN13 | $733,382 |
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 2 across 1 awards